Innovative biotechnology companies have the potential to transform healthcare, developing new therapies that may improve, as well as extend, the lives of patients. Delivering on this promise is an epic journey that may take one to two decades, unimaginable amounts of cash, and surviving the notorious valley of death. Read what Christopher J. Calhoun, Chairman & CEO of PARACRINE has to say.
Medical Device News Magazine spoke with CEO Mark Goldwasser about the potential of the medtech sector, companies that Ceros has funded so far, and what he sees ahead.
This funding will enable RetiSpec to accelerate the commercialization of its groundbreaking technology aimed at early detection of Alzheimer's disease.